- 20 February, 2018
- Posted by: partners
- Category: News
The call H2020-NMBP-TR-IND-2018-2020: Transformation of the European Industry is endowed with more than 470 million euros for the next three years.
WHAT IS THE OBJECTIVE OF THE CALL?
The aim of this call is to transform European industry through the integration of digitalization and other facilitating technologies with the aim of achieving industrial leadership at a global level, especially in terms of manufacturing and the creation of opportunities for reindustrialization.
WHAT IS THE SCOPE OF THE CALL?
The call addresses various issues:
- From the manufacturing process itself, ranging from excellence in manufacturing and flexibility to increase loyalty, precision, durability, improvement of energy efficiency and reuse of materials, to the development of skills and new forms for human interaction -machine.
- The development of emerging and potentially disruptive biotechnologies
- The development of medical technologies for diagnosis and treatment
The call is distributed around three main thematic blocks. Here is a brief description of each of them:
Factories of the future (FOF for its acronym in English)
Industrial production is a key factor of employment and creation of wealth in Europe, which contributes significantly to improving the quality of life of citizens. The manufacturing industry produces more than three-quarters of Europe’s exports and generates more than 15% of European GDP. The fundamental challenge facing the European industry today is to move from a competitive advantage based solely on cost to one of high added value. The thematic block “Factories of the Future” focuses on helping manufacturing companies, including SMEs, achieve that European added value by promoting the necessary adaptations in terms of manufacturing excellence and flexibility, including the development of skills, that manage to capitalize on the growing demand for more personalized and higher quality products. This requires the transition to a more flexible, digitized and demand-oriented manufacturing sector with lower energy consumption and waste generation, which characterizes the so-called fourth industrial revolution.
The exponential development of emerging and potentially disruptive biotechnologies has expanded its applicability in various aspects, improving the quality and quantity of products in a wide variety of sectors (welfare, environment, food, etc.), thus improving the quality of life and becoming in an important economic engine. Given that biotechnology has become a crucial element for industrial growth, an important objective is to offer added value by guaranteeing an important market share for the main European industries. In addition, Europe continues to stand out in its scientific knowledge and in the means to discover new biotechnological ideas. However, for Europe to retain its comparative advantage in biotechnology, sustained investments are needed both to feed its research base and to translate knowledge into tangible industrial innovation. In addition, the rationalized governance of new biotechnologies will facilitate the achievement of their full potential.
Innovations in Medical Technology
The demographic change of the EU requires new innovations to improve the provision of health care, the quality of life and promote active aging, being also an industrial opportunity and a growing market. To respond to these challenges and opportunities, the topics (“topics”) included in this section will promote innovative design, as well as the development and manufacture of user-centered medical technologies, including implants, tissue regeneration and nano or intelligent biomaterials.
The ecosystem of the medical industrial sector of the EU is currently fragmented in various approaches and technologies; Developing and adjusting the performance of innovative medical technologies to the needs of patients is essential to enable the translatability of “bed-side benchmark” solutions into personalized clinical applications. This development could result in a significant improvement in the quality of life of patients.
WHAT KIND OF BUSINESS ARE YOU GOING DIRECTED?
Companies that want to access European funds, knowledge and opportunities for international collaboration through collaborative projects with a strategic interest in any of the thematic priorities mentioned above.
MINIMUM POINT OF DEPARTURE
The projects submitted depending on the topic (topic) to which they are submitted should start with the following degrees of technological development (TRL):
Type of RIA action (Research and Innovation Actions): they must be based on a formulated technological concept (TRL2)
Type of action IA (Innovation Actions): they must be based on technology validated in the laboratory (TRL4)
Type of action CSA (Coordination and Support Actions) any degree of technological development
The projects must fit into any of the themes (topics) for each of the priorities mentioned above. Each theme presents a specific challenge that must be addressed, as well as the scope that is expected of the actions that are put in place within the framework of the projects.
The financing depends on the type of action of each one of the themes:
Type of action RIA (Research and Innovation Actions): 100% of direct costs are subsidized to all partners plus 25% fixed rate of indirect costs.
Type of action IA (Innovation Actions): 70% of direct costs to companies and 100% to R & D & I institutions and non-profit entities are subsidized. All of them are added a fixed rate of indirect costs of 25% applied on all direct costs except subcontracts.
Type of action CSA (Coordination and Support Actions): 100% of direct costs are subsidized to all partners plus 25% fixed rate of indirect costs.
ECONOMIC ENDOWMENT OF THE CALL
The indicative economic endowment of the call is 162 M € in 2018; 188 M € in 2019 and 122 M € in 2020.